scholarly journals Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Shree Ram Lamichhane ◽  
Thanuja Thachil ◽  
Harriet Gee ◽  
Natalie Milic

Background. Circulating microRNAs (miRNAs) are potential molecular biomarkers for cancer detection; however, little is known about their prognostic role in head and neck cancer. This current study is aimed at evaluating the role of novel miRNAs in the survival of head and neck cancer patients. Materials and Methods. We performed a systematic literature search using online databases for articles published between December 2006 and February 2019. A meta-analysis was conducted to assess the correlation between miRNA expressions and overall survival (OS) among the selected head and neck cancer studies. After multilevel screening by reviewers, meta-analysis was performed using hazard ratios (HR) and associated 95% confidence interval (CI) of survival to calculate a pooled effect size. Result. A total of 1577 patients across 13 studies were included in the literature review, with 18 miRNAs upregulated and 4 miRNAs downregulated predicting a poor overall survival. The forest plot generated using cumulated survival data resulted in a pooled HR value of 2.943 (95% CI: 2.394-3.618) indicating a strong association of dysregulated miRNA expression with a poor outcome. Only 2 miRNAs—low levels of miR-9 and high levels of miR-483-5p—were observed in two studies, both showing a significant association with overall cancer survival. Conclusion. To our knowledge, this is the first comprehensive systematic review and meta-analysis that examines the prognostic role of circulating miRNAs from blood in head and neck cancer patients. The combined effect estimates a HR across multiple studies and also supports the previous individual findings that an alteration in miRNA expression is highly associated with poor prognosis. This has the potential to use serum and/or plasma miRNAs as biomarkers and become novel tools for predicting the prognosis of head and neck cancer patients in the near future.

2019 ◽  
Vol 135 ◽  
pp. 51-57 ◽  
Author(s):  
Justin Smith ◽  
Domenico Nastasi ◽  
Reece Tso ◽  
Venkat Vangaveti ◽  
Bronia Renison ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18083-e18083
Author(s):  
Sundaram Subramanian ◽  
Naresh Somani ◽  
Shyam Ji Rawat ◽  
Sridharan Nithya ◽  
Ashwani Marwah ◽  
...  

2016 ◽  
Vol 74 (8) ◽  
pp. 1687-1694 ◽  
Author(s):  
Ingrid Klemp ◽  
Mia Steffenssen ◽  
Vivi Bakholdt ◽  
Torben Thygesen ◽  
Jens Ahm Sørensen

2019 ◽  
Vol 133 ◽  
pp. S638
Author(s):  
J. Smith ◽  
D. Nastasi ◽  
R. Tso ◽  
V. Vangaveti ◽  
B. Renison ◽  
...  

2017 ◽  
Vol 25 (9) ◽  
pp. 2969-2988 ◽  
Author(s):  
Ana Gabriela Costa Normando ◽  
Camila Lopes Rocha ◽  
Isabela Porto de Toledo ◽  
Paulo Tadeu de Souza Figueiredo ◽  
Paula Elaine Diniz dos Reis ◽  
...  

Author(s):  
Daniel Jan Toneatti ◽  
Ronny Roger Graf ◽  
John-Patrik Burkhard ◽  
Benoît Schaller

Abstract Objectives This systematic review assesses dental implant survival, calculates the incidence rate of osteoradionecrosis, and evaluates risk factors in irradiated head and neck cancer patients. Materials and methods Various databases (e.g., Medline/Embase using Ovid) and gray literature platforms were searched using a combination of keywords and subject headings. When appropriate, meta-analysis was carried out using a random effects model. Otherwise, pooled analysis was applied. Results A total of 425 of the 660 included patients received radiotherapy. In total, 2602 dental implants were placed, and 1637 were placed in irradiated patients. Implant survival after an average follow-up of 37.7 months was 97% (5% confidence interval, CI 95.2%, 95% CI 98.3%) in nonirradiated patients and 91.9% (5% CI 87.7%, 95% CI: 95.3%) after an average follow-up of 39.8 months in irradiated patients. Osteoradionecrosis occurred in 11 cases, leading to an incidence of 3% (5% CI 1.6%, 95% CI 4.9%). The main factors impacting implant survival were radiation and grafting status, while factors influencing osteoradionecrosis could not be determined using meta-analysis. Conclusion Our data show that implant survival in irradiated patients is lower than in nonirradiated patients, and osteoradionecrosis is—while rare—a serious complication that any OMF surgeon should be prepared for. The key to success could be a standardized patient selection and therapy to improve the standard of care, reduce risks and shorten treatment time. Clinical relevance Our analysis provides further evidence that implant placement is a feasible treatment option in irradiated head and neck cancer patients with diminished oral function and good long-term cancer prognosis.


Sign in / Sign up

Export Citation Format

Share Document